Revance Therapeutics (RVNC)

$3.68 +0.41 (12.54%)
Market Cap 341.36M
Revenue (ttm) 234.04M
Net Income (ttm) -323.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -138.43%
Debt to Equity Ratio -0.13
Volume 11,241,899
Avg Vol 3,025,756
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 39%
Beta 0.86
Analysts Sell
Price Target $8.43

Latest News on RVNC

Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

Jan 17, 2025, 11:45 AM EST - 12 hours ago

Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.

Jan 16, 2025, 9:15 AM EST - 1 day ago

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.

Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Jan 16, 2025, 5:45 AM EST - 1 day ago

Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Jan 15, 2025, 12:45 PM EST - 2 days ago

Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 15, 2025, 11:30 AM EST - 2 days ago

Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Revance Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 13, 2025, 11:00 AM EST - 4 days ago

Revance Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

Jan 13, 2025, 8:30 AM EST - 4 days ago

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Jan 9, 2025, 11:15 AM EST - 8 days ago

Revance Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Jan 9, 2025, 5:45 AM EST - 8 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Jan 8, 2025, 12:00 PM EST - 9 days ago

Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.

Jan 8, 2025, 10:45 AM EST - 9 days ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash

Jan 6, 2025, 9:00 AM EST - 11 days ago

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

Dec 17, 2024, 2:31 PM EST - 4 weeks ago

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

Dec 12, 2024, 8:00 AM EST - 5 weeks ago

Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

Revance agrees to lower-priced buyout offer by Crown Laboratories

Dec 9, 2024, 9:12 AM EST - 5 weeks ago

Revance agrees to lower-priced buyout offer by Crown Laboratories

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Dec 9, 2024, 8:30 AM EST - 5 weeks ago

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029

Nov 29, 2024, 4:20 AM EST - 7 weeks ago

Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029

Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC

Nov 8, 2024, 10:45 AM EST - 2 months ago

Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC

Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

Nov 7, 2024, 4:05 PM EST - 2 months ago

Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Oct 17, 2024, 4:22 PM EDT - 3 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Oct 15, 2024, 10:58 PM EDT - 3 months ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.

Aug 12, 2024, 3:18 PM EDT - 5 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal

Aug 12, 2024, 11:50 AM EDT - 5 months ago

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal

RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders

Aug 12, 2024, 9:56 AM EDT - 5 months ago

RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders